vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and First Foundation Inc. (FFWM). Click either name above to swap in a different company.
First Foundation Inc. is the larger business by last-quarter revenue ($48.4M vs $27.6M, roughly 1.8× Beta Bionics, Inc.). Beta Bionics, Inc. runs the higher net margin — -79.3% vs -97.9%, a 18.6% gap on every dollar of revenue. On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 56.6%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
BBNX vs FFWM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $48.4M |
| Net Profit | $-21.9M | $-8.0M |
| Gross Margin | 59.5% | — |
| Operating Margin | -47.4% | -97.5% |
| Net Margin | -79.3% | -97.9% |
| Revenue YoY | 56.6% | 421.7% |
| Net Profit YoY | 23.6% | 43.0% |
| EPS (diluted) | $-0.49 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | $48.4M | ||
| Q3 25 | $27.3M | $63.6M | ||
| Q2 25 | $23.2M | $51.4M | ||
| Q1 25 | $17.6M | $71.4M | ||
| Q4 24 | — | $9.3M | ||
| Q3 24 | — | $9.2M | ||
| Q2 24 | — | $57.5M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | $-8.0M | ||
| Q3 25 | $-14.2M | $-146.3M | ||
| Q2 25 | $-16.9M | $-7.7M | ||
| Q1 25 | $-28.7M | $6.9M | ||
| Q4 24 | — | $-14.1M | ||
| Q3 24 | — | $-82.2M | ||
| Q2 24 | — | $3.1M |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | — | ||
| Q3 25 | 55.5% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 50.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | -97.5% | ||
| Q3 25 | -62.5% | -92.7% | ||
| Q2 25 | -85.5% | -21.1% | ||
| Q1 25 | -105.7% | 8.8% | ||
| Q4 24 | — | -247.7% | ||
| Q3 24 | — | -1276.7% | ||
| Q2 24 | — | 4.6% |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | -97.9% | ||
| Q3 25 | -52.1% | -230.1% | ||
| Q2 25 | -72.6% | -15.0% | ||
| Q1 25 | -162.5% | 9.7% | ||
| Q4 24 | — | -152.2% | ||
| Q3 24 | — | -896.9% | ||
| Q2 24 | — | 5.4% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | $-0.09 | ||
| Q3 25 | $-0.33 | $-1.78 | ||
| Q2 25 | $-0.39 | $-0.09 | ||
| Q1 25 | $-0.93 | $0.08 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | — | $-1.23 | ||
| Q2 24 | — | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | $1.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $271.2M | $912.6M |
| Total Assets | $304.4M | $11.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | $1.6B | ||
| Q3 25 | $228.7M | $1.7B | ||
| Q2 25 | $249.7M | $1.1B | ||
| Q1 25 | $231.5M | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | $912.6M | ||
| Q3 25 | $294.8M | $917.9M | ||
| Q2 25 | $301.6M | $1.1B | ||
| Q1 25 | $313.8M | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $933.2M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | $11.9B | ||
| Q3 25 | $330.0M | $11.9B | ||
| Q2 25 | $330.0M | $11.6B | ||
| Q1 25 | $338.0M | $12.6B | ||
| Q4 24 | — | $12.6B | ||
| Q3 24 | — | $13.4B | ||
| Q2 24 | — | $13.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-31.9M |
| Free Cash FlowOCF − Capex | — | $-35.2M |
| FCF MarginFCF / Revenue | — | -72.8% |
| Capex IntensityCapex / Revenue | — | 6.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-45.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | $-31.9M | ||
| Q3 25 | $-8.7M | $9.2M | ||
| Q2 25 | $-13.6M | $-16.3M | ||
| Q1 25 | $-20.0M | $-552.0K | ||
| Q4 24 | — | $-8.7M | ||
| Q3 24 | — | $14.2M | ||
| Q2 24 | — | $-9.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | $-35.2M | ||
| Q3 25 | $-10.0M | $8.6M | ||
| Q2 25 | $-15.4M | $-16.7M | ||
| Q1 25 | $-20.3M | $-2.5M | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $13.4M | ||
| Q2 24 | — | $-9.4M |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | -72.8% | ||
| Q3 25 | -36.7% | 13.5% | ||
| Q2 25 | -66.2% | -32.4% | ||
| Q1 25 | -115.1% | -3.5% | ||
| Q4 24 | — | -123.5% | ||
| Q3 24 | — | 146.2% | ||
| Q2 24 | — | -16.3% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 6.9% | ||
| Q3 25 | 4.7% | 1.0% | ||
| Q2 25 | 7.7% | 0.8% | ||
| Q1 25 | 1.9% | 2.8% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | — | 9.0% | ||
| Q2 24 | — | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
